B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

TBXA2R

MOLECULAR TARGET

thromboxane A2 receptor

UniProt: P21731NCBI Gene: 691525 compounds

TBXA2R (thromboxane A2 receptor) is targeted by 25 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting TBXA2R

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Dinoprost1.393
2Aripiprazole1.102
3Dinoprostone1.102
4Amlodipine0.691
5cbd0.691
6Losartan0.691
7Simvastatin0.691
8Axitinib0.691
9candesartan cilexetil [Supplementary Concept]0.691
10cannabidiol0.691
11Cloprostenol0.691
12Enoxacin0.691
13Epirubicin0.691
14Ezetimibe0.691
15Flutamide0.691
16Irbesartan0.691
17Micafungin0.691
18Nicergoline0.691
19Norethindrone Acetate Acetate ester of norethindrone that is used as0.691
20Pioglitazone0.691
21Rifamycins0.691
22Rifamycins0.691
23Ritonavir0.691
24Thiethylperazine0.691
25Ticagrelor0.691

About TBXA2R as a Drug Target

TBXA2R (thromboxane A2 receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 25 compounds with documented TBXA2R interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

TBXA2R inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.